Zydus plans to launch ulcer drug mesalamine in US by March 2020

Zydus Cadila plans to a launch a generic version of ulcer drug Delzicol (mesalamine) in March 2020 in the US, following a settlement agreement with the drug’s patent-holder Allergan.

“The patent litigation relating to Allergan’s Delzicol (mesalamine) has been settled. As a result of the settlement, and if approved by US FDA, its US subsidiary, Zydus Pharmaceuticals (USA) Inc, will be able to market its generic version of Delzicol in the US beginning on March 1, 2020, or earlier under certain circumstances,” said Zydus Cadila in a BSE filing on December 3, 2016.

Mesalamine delayed-release tablets are indicated for the treatment of moderately active ulcerative colitis in adults.